Therapeutic treatment for the coronavirus disease covid-19

ABSTRACT

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after the patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of the herb thyme, also know as common thyme (Thymus vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional PatentApplication No. 63/100,831 titled “Medical herbal treatment” filed Apr.2, 2020 and U.S. Provisional Patent Application No. 63/102,925 titled“Medical herbal coronavirus treatment” filed Jul. 8, 2020, the contentsof which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

Information from Wikipedia on 2021 Mar. 27 on pages 1 through 17.

Coronaviruses are a group of related RNA viruses that cause diseases inmammals and birds. In humans and birds, they cause respiratory tractinfections that can range from mild to lethal. Mild illnesses in humansinclude some cases of the common cold (which is also caused by otherviruses, predominantly rhinoviruses), while more lethal varieties cancause SARS, MERS, and COVID-19. In cows and pigs they cause diarrhea,while in mice they cause hepatitis and encephalomyelitis.

Coronaviruses constitute the subfamily Orthocoronavirinae, in the familyCoronaviridae, order Nidovirales, and realm Riboviria. They areenveloped viruses with a positive-sense single-stranded RNA genome and anucleocapsid of helical symmetry. The genome size of coronavirusesranges from approximately 26 to 32 kilobases, one of the largest amongRNA viruses. They have characteristic club-shaped spikes that projectfrom their surface, which in electron micrographs create an imagereminiscent of the solar corona, from which their name derives.

Etymology

The name “coronavirus” is derived from Latin corona, meaning “crown” or“wreath”, itself a borrowing from Greek ______ kor_n_, “garland, wreath”The name was coined by June Almeida and David Tyrrell who first observedand studied human coronaviruses. The word was first used in print in1968 by an informal group of virologists in the journal Nature todesignate the new family of viruses. The name refers to thecharacteristic appearance of virions (the infective form of the virus)by electron microscopy, which have a fringe of large, bulbous surfaceprojections creating an image reminiscent of the solar corona or halo.This morphology is created by the viral spike peplomers, which areproteins on the surface of the virus.

The scientific name Coronavirus was accepted as a genus name by theInternational Committee for the Nomenclature of Viruses (later renamedInternational Committee on Taxonomy of Viruses) in 1971. As the numberof new species increased, the genus was split into four genera, namelyAlphacoronavirus, Betacoronavirus, Deltacoronavirus, andGammacoronavirus in 2009. The common name coronavirus is used to referto any member of the subfamily Orthocoronavirinae. As of 2020, 45species are officially recognised.

History

The earliest reports of a coronavirus infection in animals occurred inthe late 1920s, when an acute respiratory infection of domesticatedchickens emerged in North America. Arthur Schalk and M. C. Hawn in 1931made the first detailed report which described a new respiratoryinfection of chickens in North Dakota. The infection of new-born chickswas characterized by gasping and listlessness with high mortality ratesof 40-90%. Leland David Bushnell and Carl Alfred Brandly isolated thevirus that caused the infection in 1933. The virus was then known asinfectious bronchitis virus (IBV). Charles D. Hudson and Fred RobertBeaudette cultivated the virus for the first time in 1937. The specimencame to be known as the Beaudette strain. In the late 1940s, two moreanimal coronaviruses, JHM that causes brain disease (murineencephalitis) and mouse hepatitis virus (MHV) that causes hepatitis inmice were discovered. It was not realized at the time that these threedifferent viruses were related.

Human coronaviruses were discovered in the 1960s using two differentmethods in the United Kingdom and the United States. E. C. Kendall,Malcolm Bynoe, and David Tyrrell working at the Common Cold Unit of theBritish Medical Research Council collected a unique common cold virusdesignated B814 in 1961. The virus could not be cultivated usingstandard techniques which had successfully cultivated rhinoviruses,adenoviruses and other known common cold viruses. In 1965, Tyrrell andBynoe successfully cultivated the novel virus by serially passing itthrough organ culture of human embryonic trachea. The new cultivatingmethod was introduced to the lab by Bertil Hoorn. The isolated viruswhen intranasally inoculated into volunteers caused a cold and wasinactivated by ether which indicated it had a lipid envelope. DorothyHamre and John Procknow at the University of Chicago isolated a novelcold from medical students in 1962. They isolated and grew the virus inkidney tissue culture, designating it 229E. The novel virus caused acold in volunteers and, like B814, was inactivated by ether.

Transmission electron micrograph of organ cultured coronavirus OC43Scottish virologist June Almeida at St. Thomas Hospital in London,collaborating with Tyrrell, compared the structures of IBV, B814 and229E in 1967. Using electron microscopy the three viruses were shown tobe morphologically related by their general shape and distinctiveclub-like spikes. A research group at the National Institute of Healththe same year was able to isolate another member of this new group ofviruses using organ culture and named one of the samples OC43 (OC fororgan culture). Like B814, 229E, and IBV, the novel cold virus OC43 haddistinctive club-like spikes when observed with the electron microscope.

The IBV-like novel cold viruses were soon shown to be alsomorphologically related to the mouse hepatitis virus. This new group ofviruses were named coronaviruses after their distinctive morphologicalappearance. Human coronavirus 229E and human coronavirus OC43 continuedto be studied in subsequent decades. The coronavirus strain B814 waslost. It is not known which present human coronavirus it was. Otherhuman coronaviruses have since been identified, including SARS-CoV in2003, HCoV NL63 in 2003, HCoV HKU1 in 2004, MERS-CoV in 2013, andSARS-CoV-2 in 2019. There have also been a large number of animalcoronaviruses identified since the 1960s.

Microbiology

Structure of a Coronavirus:

Coronaviruses are large, roughly spherical particles with unique surfaceprojections. Their size is highly variable with average diameters of 80to 120 nm. Extreme sizes are known from 50 to 200 nm in diameter. Thetotal molecular weight is on average 40,000 kDa. They are enclosed in anenvelope embedded with a number of protein molecules. The lipid bilayerenvelope, membrane proteins, and nucleocapsid protect the virus when itis outside the host cell.

The viral envelope is made up of a lipid bilayer in which the membrane(M), envelope (E) and spike (S) structural proteins are anchored. Themolar ratio of E:S:M in the lipid bilayer is approximately 1:20:300. TheE and M protein are the structural proteins that combined with the lipidbilayer to shape the viral envelope and maintain its size. S proteinsare needed for interaction with the host cells. But human coronavirusNL63 is peculiar in that its M protein has the binding site for the hostcell, and not its S protein. The diameter of the envelope is 85 nm. Theenvelope of the virus in electron micrographs appears as a distinct pairof electron-dense shells (shells that are relatively opaque to theelectron beam used to scan the virus particle).

The M protein is the main structural protein of the envelope thatprovides the overall shape and is a type III membrane protein. Itconsists of 218 to 263 amino acid residues and forms a layer 7.8 nmthick. It has three domains, a short N-terminal ectodomain, atriple-spanning transmembrane domain, and a C-terminal endodomain. TheC-terminal domain forms a matrix-like lattice that adds to theextra-thickness of the envelope. Different species can have either N- or0-linked glycans in their protein amino-terminal domain. The M proteinis crucial during the assembly, budding, envelope formation, andpathogenesis stages of the virus lifecycle.

The E proteins are minor structural proteins and highly variable indifferent species. There are only about 20 copies of the E proteinmolecule in a coronavirus particle. They are 8.4 to 12 kDa in size andare composed of 76 to 109 amino acids. They are integral proteins (i.e.embedded in the lipid layer) and have two domains namely a transmembranedomain and an extramembrane C-terminal domain. They are almostfully_-helical, with a single_-helical transmembrane domain, and formpentameric (five-molecular) ion channels in the lipid bilayer. They areresponsible for virion assembly, intracellular trafficking andmorphogenesis (budding).

The spikes are the most distinguishing feature of coronaviruses and areresponsible for the corona- or halo-like surface. On average acoronavirus particle has 74 surface spikes. Each spike is about 20 nmlong and is composed of a trimer of the S protein. The S protein is inturn composed of an S1 and S2 subunit. The homotrimeric S protein is aclass I fusion protein which mediates the receptor binding and membranefusion between the virus and host cell. The S1 subunit forms the head ofthe spike and has the receptor-binding domain (RBD). The S2 subunitforms the stem which anchors the spike in the viral envelope and onprotease activation enables fusion. The two subunits remainnoncovalently linked as they are exposed on the viral surface until theyattach to the host cell membrane. In a functionally active state, threeS1 are attached to two S2 subunits. The subunit complex is split intoindividual subunits when the virus binds and fuses with the host cellunder the action of proteases such as cathepsin family and transmembraneprotease serine 2 (TMPRSS2) of the host cell.

After binding of the ACE2 receptor, SARS-CoV spike is activated andcleaved at the S1/S2 level S1 proteins are the most critical componentsin terms of infection. They are also the most variable components asthey are responsible for host cell specificity. They possess two majordomains named N-terminal domain (S1-NTD) and C-terminal domain (S1-CTD),both of which serve as the receptor-binding domains. The NTDs recognizeand bind sugars on the surface of the host cell. An exception is the MHVNTD that binds to a protein receptor carcinoembryonic antigen-relatedcell adhesion molecule 1 (CEACAM1). S1-CTDs are responsible forrecognizing different protein receptors such as angiotensin-convertingenzyme 2 (ACE2), aminopeptidase N (APN), and dipeptidyl peptidase 4(DPP4).

A subset of coronaviruses (specifically the members of betacoronavirussubgroup A) also has a shorter spike-like surface protein calledhemagglutinin esterase (HE). The HE proteins occur as homodimerscomposed of about 400 amino acid residues and are 40 to 50 kDa in size.They appear as tiny surface projections of 5 to 7 nm long embedded inbetween the spikes. They help in the attachment to and detachment fromthe host cell.

Inside the envelope, there is the nucleocapsid, which is formed frommultiple copies of the nucleocapsid (N) protein, which are bound to thepositive-sense single-stranded RNA genome in a continuousbeads-on-a-string type conformation. N protein is a phosphoprotein of 43to 50 kDa in size, and is divided into three conserved domains. Themajority of the protein is made up of domains 1 and 2, which aretypically rich in arginines and lysines. Domain 3 has a short carboxyterminal end and has a net negative charge due to excess of acidic overbasic amino acid residues.

Genome

SARS-CoV Genome and Proteins:

Coronaviruses contain a positive-sense, single-stranded RNA genome. Thegenome size for coronaviruses ranges from 26.4 to 31.7 kilobases. Thegenome size is one of the largest among RNA viruses. The genome has a5_methylated cap and a 3_polyadenylated tail. The genome organizationfor a coronavirus is 5_-leader-UTR-replicase (ORF1ab)-spike (S)-envelope(E)-membrane (M)-nucleocapsid (N)-3_UTR-poly (A) tail. The open readingframes 1a and 1b, which occupy the first two-thirds of the genome,encode the replicase polyprotein (pp1 ab). The replicase polyproteinself cleaves to form 16 nonstructural proteins (nsp1-nsp16). The laterreading frames encode the four major structural proteins: spike,envelope, membrane, and nucleocapsid. Interspersed between these readingframes are the reading frames for the accessory proteins. The number ofaccessory proteins and their function is unique depending on thespecific coronavirus.

Replication Cycle

Cell Entry and the Life Cycle of a Coronavirus:

Infection begins when the viral spike protein attaches to itscomplementary host cell receptor. After attachment, a protease of thehost cell cleaves and activates the receptor-attached spike protein.Depending on the host cell protease available, cleavage and activationallows the virus to enter the host cell by endocytosis or direct fusionof the viral envelope with the host membrane.

Genome Translation

On entry into the host cell, the virus particle is uncoated, and itsgenome enters the cell cytoplasm. The coronavirus RNA genome has a5_methylated cap and a 3_polyadenylated tail, which allows it to actlike a messenger RNA and be directly translated by the host cell'sribosomes. The host ribosomes translate the initial overlapping openreading frames ORF1a and ORF1b of the virus genome into two largeoverlapping polyproteins, pp1a and pp1ab.

The larger polyprotein pp1ab is a result of a −1 ribosomal frameshiftcaused by a slippery sequence (UUUAAAC) and a downstream RNA pseudoknotat the end of open reading frame ORF1a. The ribosomal frameshift allowsfor the continuous translation of ORF1a followed by ORF1b. Thepolyproteins have their own proteases, PLpro (nsp3) and 3CLpro (nsp5),which cleave the polyproteins at different specific sites. The cleavageof polyprotein pp1 ab yields 16 nonstructural proteins (nsp1 to nsp16).Product proteins include various replication proteins such asRNA-dependent RNA polymerase (nsp12), RNA helicase (nsp13), andexoribonuclease (nsp14).

Replicase-Transcriptase

Replicase-Transcriptase Complex:

A number of the nonstructural proteins coalesce to form a multi-proteinreplicase-transcriptase complex. The main replicase-transcriptaseprotein is the RNA-dependent RNA polymerase (RdRp). It is directlyinvolved in the replication and transcription of RNA from an RNA strand.The other nonstructural proteins in the complex assist in thereplication and transcription process. The exoribonuclease nonstructuralprotein, for instance, provides extra fidelity to replication byproviding a proofreading function which the RNA-dependent RNA polymeraselacks. Replication—One of the main functions of the complex is toreplicate the viral genome. RdRp directly mediates the synthesis ofnegative-sense genomic RNA from the positive-sense genomic RNA. This isfollowed by the replication of positive-sense genomic RNA from thenegative-sense genomic RNA.

Transcription of Nested mRNAs and Nested Set of Subgenomic mRNAs:

Transcription—The other important function of the complex is totranscribe the viral genome. RdRp directly mediates the synthesis ofnegative-sense subgenomic RNA molecules from the positive-sense genomicRNA. This process is followed by the transcription of thesenegative-sense subgenomic RNA molecules to their correspondingpositive-sense mRNAs. The subgenomic mRNAs form a “nested set” whichhave a common 5′-head and partially duplicate 3′-end. Recombination—Thereplicase-transcriptase complex is also capable of genetic recombinationwhen at least two viral genomes are present in the same infected cell.RNA recombination appears to be a major driving force in determininggenetic variability within a coronavirus species, the capability of acoronavirus species to jump from one host to another and, infrequently,in determining the emergence of novel coronaviruses. The exact mechanismof recombination in coronaviruses is unclear, but likely involvestemplate switching during genome replication.

Assembly and Release

The replicated positive-sense genomic RNA becomes the genome of theprogeny viruses. The mRNAs are gene transcripts of the last third of thevirus genome after the initial overlapping reading frame. These mRNAsare translated by the host's ribosomes into the structural proteins anda number of accessory proteins. RNA translation occurs inside theendoplasmic reticulum. The viral structural proteins S, E, and M movealong the secretory pathway into the Golgi intermediate compartment.There, the M proteins direct most protein-protein interactions requiredfor assembly of viruses following its binding to the nucleocapsid.Progeny viruses are then released from the host cell by exocytosisthrough secretory vesicles. Once released the viruses can infect otherhost cells.

Transmission

Infected carriers are able to shed viruses into the environment. Theinteraction of the coronavirus spike protein with its complementary cellreceptor is central in determining the tissue tropism, infectivity, andspecies range of the released virus. Coronaviruses mainly targetepithelial cells. They are transmitted from one host to another host,depending on the coronavirus species, by either an aerosol, fomite, orfecal-oral route.

Human coronaviruses infect the epithelial cells of the respiratorytract, while animal coronaviruses generally infect the epithelial cellsof the digestive tract. SARS coronavirus, for example, infects the humanepithelial cells of the lungs via an aerosol route by binding to theangiotensin-converting enzyme 2 (ACE2) receptor. Transmissiblegastroenteritis coronavirus (TGEV) infects the pig epithelial cells ofthe digestive tract via a fecal-oral route by binding to the alanineaminopeptidase (APN) receptor.

Classification

Phylogenetic Tree of Coronaviruses:

Coronaviruses form the subfamily Orthocoronavirinae, which is one of twosub-families in the family Coronaviridae, order Nidovirales, and realmRiboviria. They are divided into the four genera: Alphacoronavirus,Betacoronavirus, Gammacoronavirus and Deltacoronavirus.Alphacoronaviruses and betacoronaviruses infect mammals, whilegammacoronaviruses and deltacoronaviruses primarily infect birds. Genus:Alphacoronavirus; type species: Alphacoronavirus Species:Alphacoronavirus 1 (TGEV, Feline coronavirus, Canine coronavirus), Humancoronavirus 229E, Human coronavirus NL63, Miniopterus bat coronavirus 1,Miniopterus bat coronavirus HKU8, Porcine epidemic diarrhea virus,Rhinolophus bat coronavirus HKU2, Scotophilus bat coronavirus 512 GenusBetacoronavirus; type species: Murine coronavirus (MHV) Species:Betacoronavirus 1 (Bovine Coronavirus, Human coronavirus OC43), Hedgehogcoronavirus 1, Human coronavirus HKU1, Middle East respiratorysyndrome-related coronavirus, Murine coronavirus, Pipistrellus batcoronavirus HKU5, Rousettus bat coronavirus HKU9, Severe acuterespiratory syndrome-related coronavirus (SARS-CoV, SARS-CoV-2),Tylonycteris bat coronavirus HKU4 Genus Gammacoronavirus; type species:Avian coronavirus (IBV) Species: Avian coronavirus, Beluga whalecoronavirus SW1 Genus Deltacoronavirus; type species: Bulbul coronavirusHKU11 Species: Bulbul coronavirus HKU11, Porcine coronavirus HKU15

Origin

Origins of Human Coronaviruses with Possible Intermediate Hosts:

The most recent common ancestor (MRCA) of all coronaviruses is estimatedto have existed as recently as 8000 BCE, although some models place thecommon ancestor as far back as 55 million years or more, implying longterm coevolution with bat and avian species. The most recent commonancestor of the alphacoronavirus line has been placed at about 2400 BCE,of the betacoronavirus line at 3300 BCE, of the gammacoronavirus line at2800 BCE, and of the deltacoronavirus line at about 3000 BCE. Bats andbirds, as warm-blooded flying vertebrates, are an ideal naturalreservoir for the coronavirus gene pool (with bats the reservoir foralphacoronaviruses and betacoronavirus—and birds the reservoir forgammacoronaviruses and deltacoronaviruses). The large number and globalrange of bat and avian species that host viruses has enabled extensiveevolution and dissemination of coronaviruses.

Many human coronaviruses have their origin in bats. The humancoronavirus NL63 shared a common ancestor with a bat coronavirus(ARCoV.2) between 1190 and 1449 CE. The human coronavirus 229E shared acommon ancestor with a bat coronavirus (GhanaGrpl Bt CoV) between 1686and 1800 CE. More recently, alpaca coronavirus and human coronavirus229E diverged sometime before 1960. MERS-CoV emerged in humans from batsthrough the intermediate host of camels. MERS-CoV, although related toseveral bat coronavirus species, appears to have diverged from theseseveral centuries ago. The most closely related bat coronavirus andSARS-CoV diverged in 1986. The ancestors of SARS-CoV first infectedleaf-nose bats of the genus Hipposideridae; subsequently, they spread tohorseshoe bats in the species Rhinolophidae, then to Asian palm civets,and finally to humans.

Unlike other betacoronaviruses, bovine coronavirus of the speciesBetacoronavirus 1 and subgenus Embecovirus is thought to have originatedin rodents and not in bats. In the 1790s, equine coronavirus divergedfrom the bovine coronavirus after a cross-species jump. Later in the1890s, human coronavirus OC43 diverged from bovine coronavirus afteranother cross-species spillover event. It is speculated that the flupandemic of 1890 may have been caused by this spillover event, and notby the influenza virus, because of the related timing, neurologicalsymptoms, and unknown causative agent of the pandemic. Besides causingrespiratory infections, human coronavirus OC43 is also suspected ofplaying a role in neurological diseases. In the 1950s, the humancoronavirus OC43 began to diverge into its present genotypes.Phylogentically, mouse hepatitis virus (Murine coronavirus), whichinfects the mouse's liver and central nervous system, is related tohuman coronavirus OC43 and bovine coronavirus. Human coronavirus HKU1,like the aforementioned viruses, also has its origins in rodents.

Infection in Humans

Transmission and Life-Cycle of SARS-CoV-2 Causing COVID-19:

Coronaviruses vary significantly in risk factor. Some can kill more than30% of those infected, such as MERS-CoV, and some are relativelyharmless, such as the common cold. Coronaviruses can cause colds withmajor symptoms, such as fever, and a sore throat from swollen adenoids.Coronaviruses can cause pneumonia (either direct viral pneumonia orsecondary bacterial pneumonia) and bronchitis (either direct viralbronchitis or secondary bacterial bronchitis). The human coronavirusdiscovered in 2003, SARS-CoV, which causes severe acute respiratorysyndrome (SARS), has a unique pathogenesis because it causes both upperand lower respiratory tract infections.

Six species of human coronaviruses are known, with one speciessubdivided into two different strains, making seven strains of humancoronaviruses altogether.

Seasonal distribution of HCoV-NL63 in Germany shows a preferentialdetection from November to March. Four human coronaviruses producesymptoms that are generally mild, even though it is contended they mighthave been more aggressive in the past:

-   -   Human coronavirus OC43 (HCoV-OC43), _-CoV    -   Human coronavirus HKU1 (HCoV-HKU1), _-CoV    -   Human coronavirus 229E (HCoV-229E), _-CoV    -   Human coronavirus NL63 (HCoV-NL63), _-CoV

Three human coronaviruses produce symptoms that are potentially severe:

-   -   Middle East respiratory syndrome-related coronavirus (MERS-CoV),        _-CoV    -   Severe acute respiratory syndrome coronavirus (SARS-CoV), _-CoV    -   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),        _-CoV

Common Cold

Although the common cold is usually caused by rhinoviruses, in about 15%of cases the cause is a coronavirus. The human coronaviruses HCoV-OC43,HCoV-HKU1, HCoV-229E, and HCoV-NL63 continually circulate in the humanpopulation in adults and children worldwide and produce the generallymild symptoms of the common cold. The four mild coronaviruses have aseasonal incidence occurring in the winter months in temperate climates.There is no preponderance in any season in tropical climates.

Severe Acute Respiratory Syndrome (SARS)

Characteristics of Zoonotic Coronavirus Strains:

MERS-CoV, SARS-CoV, SARS-CoV-2, and related diseases MERS-CoV SARS-CoVSARS-CoV-2 Disease MERS SARS COVID-19 Outbreaks 2012, 2015, 2002-20042019-2021 2018 pandemic Epidemiology Date of first June NovemberDecember identified case 2012 2002 2019 Location of first Jeddah,Shunde, Wuhan, identified case Saudi Arabia China China Age average  56 44 56 Sex ratio (M:F) 3.3:1 0.8:1 1.6:1 Confirmed cases 2494 8096126,751,929 Deaths  858  774 2,778,310 Case fatality rate 37%  9.2% 2.2%Symptoms Fever 98% 99-100%  87.9% Dry cough 47% 29-75% 67.7% Dyspnea 72%40-42% 18.6% Diarrhea 26% 20-25% 3.7% Sore throat 21% 13-25% 13.9%Ventilatory use 24.5%  14-20% 4.1% Notes a {circumflex over ( )} Basedon data from Hong Kong. b {circumflex over ( )} Jump up to: _(—) ^(a b)Data as of 28 March 2021. • vte

In 2003, following the outbreak of severe acute respiratory syndrome(SARS) which had begun the prior year in Asia, and secondary caseselsewhere in the world, the World Health Organization (WHO) issued apress release stating that a novel coronavirus identified by a number oflaboratories was the causative agent for SARS. The virus was officiallynamed the SARS coronavirus (SARS-CoV). More than 8,000 people from 29different countries and territories were infected, and at least 774died.

Middle East Respiratory Syndrome (MERS)

In September 2012, a new type of coronavirus was identified, initiallycalled Novel Coronavirus 2012, and now officially named Middle Eastrespiratory syndrome coronavirus (MERS-CoV). The World HealthOrganization issued a global alert soon after.^([112]) The WHO update on28 Sep. 2012 said the virus did not seem to pass easily from person toperson. However, on 12 May 2013, a case of human-to-human transmissionin France was confirmed by the French Ministry of Social Affairs andHealth. In addition, cases of human-to-human transmission were reportedby the Ministry of Health in Tunisia. Two confirmed cases involvedpeople who seemed to have caught the disease from their late father, whobecame ill after a visit to Qatar and Saudi Arabia. Despite this, itappears the virus had trouble spreading from human to human, as mostindividuals who are infected do not transmit the virus. By 30 Oct. 2013,there were 124 cases and 52 deaths in Saudi Arabia.

After the Dutch Erasmus Medical Centre sequenced the virus, the viruswas given a new name, Human Coronavirus-Erasmus Medical Centre(HCoV-EMC). The final name for the virus is Middle East respiratorysyndrome coronavirus (MERS-CoV). The only U.S. cases (both survived)were recorded in May 2014.

In May 2015, an outbreak of MERS-CoV occurred in the Republic of Korea,when a man who had traveled to the Middle East, visited four hospitalsin the Seoul area to treat his illness. This caused one of the largestoutbreaks of MERS-CoV outside the Middle East. As of December 2019,2,468 cases of MERS-CoV infection had been confirmed by laboratorytests, 851 of which were fatal, a mortality rate of approximately 34.5%.

Coronavirus Disease 2019 (COVID-19)

In December 2019, a pneumonia outbreak was reported in Wuhan, China. On31 Dec. 2019, the outbreak was traced to a novel strain of coronavirus,which was given the interim name 2019-nCoV by the World HealthOrganization (WHO), later renamed SARS-CoV-2 by the InternationalCommittee on Taxonomy of Viruses.

As of 28 Mar. 2021, there have been at least 2,778,310 confirmed deathsand more than 126,751,929 confirmed cases in the COVID-19 pandemic. TheWuhan strain has been identified as a new strain of Betacoronavirus fromgroup 2B with approximately 70% genetic similarity to the SARS-CoV. Thevirus has a 96% similarity to a bat coronavirus, so it is widelysuspected to originate from bats as well.

Infection in Animals

Coronaviruses have been recognized as causing pathological conditions inveterinary medicine since the 1930s. They infect a range of animalsincluding swine, cattle, horses, camels, cats, dogs, rodents, birds andbats. The majority of animal related coronaviruses infect the intestinaltract and are transmitted by a fecal-oral route. Significant researchefforts have been focused on elucidating the viral pathogenesis of theseanimal coronaviruses, especially by virologists interested in veterinaryand zoonotic diseases.

Farm Animals

Coronaviruses infect domesticated birds. Infectious bronchitis virus(IBV), a type of coronavirus, causes avian infectious bronchitis. Thevirus is of concern to the poultry industry because of the highmortality from infection, its rapid spread, and its effect onproduction. The virus affects both meat production and egg productionand causes substantial economic loss. In chickens, infectious bronchitisvirus targets not only the respiratory tract but also the urogenitaltract. The virus can spread to different organs throughout the chicken.The virus is transmitted by aerosol and food contaminated by feces.Different vaccines against IBV exist and have helped to limit the spreadof the virus and its variants. Infectious bronchitis virus is one of anumber of strains of the species Avian coronavirus. Another strain ofavian coronavirus is turkey coronavirus (TCV) which causes enteritis inturkeys.

Coronaviruses also affect other branches of animal husbandry such as pigfarming and the cattle raising. Swine acute diarrhea syndromecoronavirus (SADS-CoV), which is related to bat coronavirus HKU2, causesdiarrhea in pigs. Porcine epidemic diarrhea virus (PEDV) is acoronavirus that has recently emerged and similarly causes diarrhea inpigs. Transmissible gastroenteritis virus (TGEV), which is a member ofthe species Alphacoronavirus 1, is another coronavirus that causesdiarrhea in young pigs. In the cattle industry bovine coronavirus (BCV),which is a member of the species Betacoronavirus 1 and related toHCoV-OC43, is responsible for severe profuse enteritis in young calves.

Domestic Pets

Coronaviruses infect domestic pets such as cats, dogs, and ferrets.There are two forms of feline coronavirus which are both members of thespecies Alphacoronavirus 1. Feline enteric coronavirus is a pathogen ofminor clinical significance, but spontaneous mutation of this virus canresult in feline infectious peritonitis (FTP), a disease with highmortality. There are two different coronaviruses that infect dogs.Canine coronavirus (CCoV), which is a member of the speciesAlphacoronavirus 1, causes mild gastrointestinal disease. Caninerespiratory coronavirus (CRCoV), which is a member of the speciesBetacoronavirus 1 and related to HCoV-OC43, cause respiratory disease.Similarly, there are two types of coronavirus that infect ferrets.Ferret enteric coronavirus causes a gastrointestinal syndrome known asepizootic catarrhal enteritis (ECE), and a more lethal systemic versionof the virus (like FIP in cats) known as ferret systemic coronavirus(FSC).

Laboratory Animals

Coronaviruses infect laboratory animals, Mouse hepatitis virus (MHV),which is a member of the species Murine coronavirus, causes an epidemicmurine illness with high mortality, especially among colonies oflaboratory mice. Prior to the discovery of SARS-CoV, MHV was thebest-studied coronavirus both in vivo and in vitro as well as at themolecular level. Some strains of MHV cause a progressive demyelinatingencephalitis in mice which has been used as a murine model for multiplesclerosis. Sialodacryoadenitis virus (SDAV), which is a strain of thespecies Murine coronavirus, is highly infectious coronavirus oflaboratory rats, which can be transmitted between individuals by directcontact and indirectly by aerosol. Rabbit enteric coronavirus causesacute gastrointestinal disease and diarrhea in young European rabbits.Mortality rates are high.

Prevention and Treatment

A number of vaccines using different methods have been developed againsthuman coronavirus SARS-CoV-2. Antiviral targets against humancoronaviruses have also been identified such as viral proteases,polymerases, and entry proteins. Drugs are in development which targetthese proteins and the different steps of viral replication. Vaccinesare available for animal coronaviruses IBV, TGEV, and Canine CoV,although their effectiveness is limited. In the case of outbreaks ofhighly contagious animal coronaviruses, such as PEDV, measures such asdestruction of entire herds of pigs may be used to prevent transmissionto other herds.

End of the Wikipedia information on 2021-03-27.

SUMMARY OF THE INVENTION

The disclosed invention comprises medical therapeutic treatment methodsand compositions for a new use of the herb thyme, the new use can alsobe described as a second medical use since the herb thyme has beenprevious used to treat various types of viral infections. The herb thymeis also known as Common Thyme or Spanish Thyme. The new use of the herbthyme is for the treatment of the Coronavirus COVID-19 disease and thesymptoms of Covid-19 disease, and likely for the prevention of Covid-19disease. In addition to the new use of the herb thyme, a method of usefor the herb thyme for the treatment of COVID-19 disease and itssymptoms is also disclosed. The herb thyme and its compounds havepreviously been shown to have antiviral activity against certain virusesin medical studies.

One such comparative study is antiviral activity against herpes simplexvirus type 1 (HSV-1) in vitro as described in a comparative studypublished in The National Library of Medicine NIH 8600 Rockville PikeBethesda, Md. 20894, PubMed.gov titled “Comparative study on theantiviral activity of selected monoterpenes derived from essential oils”Phytother Res 2010 May; 24(5):673-9. doi: 10.1002/ptr.2955.

Another comparative study published by PubMed.gov is titled “EssentialOils for the Treatment of Herpes Simplex Virus Infections”. Chemotherapy2019; 64(1):1-7. doi: 10.1159/000501062. Epub 2019 Jun. 24.

And still another comparative study published by PubMed.gov is titled“Inhibition of herpes simplex virus type 1 by thymol-relatedmonoterpenoids” Planta Med. 2012 October; 78(15):1636-8. doi:10.1055/s-0032-1315208. Epub 2012 Aug. 13.

And yet still another comparative study published by PubMed.gov istitled “Susceptibility of herpes simplex virus type 1 to monoterpenesthymol, carvacrol, p-cymene and essential oils of Sinapis arvensis L.,Lallemantia royleana Benth. and Pulicaria vulgaris Gaertn”. 2017 Aug.30; 63(8):42-47. doi: 10.14715/cmb/2017.63.8.10. Cell Mol Biol(Noisy-le-grand)

In addition to the above four studies by The National Library ofMedicine NIH PubMed.gov, is an additional study in The Journal of PlantMedicines by Case Adams, PHD, Oct. 3, 2017 (Last Updated On: Apr. 17,2018) titled “Thyme Antiviral Against Herpes and Other Viruses”. Thefive above disclosed studies mention the antiviral activity andeffectiveness of the herb thyme and of certain components of the herbthyme such as thymol in treating certain viral diseases, suggesting theherb thyme and its known antiviral components as being a second usetreatment of disease for use in treating the disease Covid-19. Some ofthe many antiviral substances in the herb thyme may be thymol, camphor,borneol, carvacrol, terpinenes, pinenes, cymene, terpinenols, citral andcineoles, and any one of or combination thereof these constituents maybe beneficial for use in the treatment of the disease Covid-19.

DESCRIPTION OF THE INVENTION

The disclosed invention comprises a composition and treatment to preventthe progression and severity of COVID-19 after infection and theoccurrence of symptoms of the disease, the treatment is to be initiatedsoon after the patient develops the first signs of symptoms andpreferably initiated within approximately twenty four hours of the onsetof symptoms of the disease. The symptoms of the disease comprising butnot limited to individually or in combination thereof being fever,headache, sore joints, cough, fatigue, and chills. Generally the fevermay be mild or moderate in the initial symptoms stage. The treatmentconsists of the oral administration of the herb thyme, also know ascommon thyme (Thymus Vulgaris). Generally the leaf of the herb is usedand the leaf of the herb is generally ground into powder for easyassimilation by the digestive tract of the patient. Oral administrationof the whole non-ground leaf of the herb thyme has not been tested,although, it is conceivable that the whole leaf in an un-ground state ofthe herb may not digest fully by the patients digestive system and maynot achieve the desired results of the treatment. The disclosedtreatment is thought to inhibit the replication and activity of thevirus allowing the patient to regain normal health and assist indeveloping immunity to the virus. The disclosed treatment is not knownto completely eliminate the coronavirus from the patient thereforeresulting in the patient possibly developing the same or similarsymptoms of the disease a second or more subsequent times, thereforerequiring additional disclosed treatments of the oral administration ofthe herb thyme.

The herb Thyme in a ground, powdered form and ingested with water in thedisclosed treatment method has be shown to reduce and eliminate thesymptoms and Covid-19 disease sickness in a single disclosed patientthat developed the symptoms of COVID-19 on two different occasionsspaced approximately twelve days apart. The disclosed patient recoveredfrom the symptoms each of the two times and was able to return back tohis normal working routine within approximately two days. The disclosedpatient was treated each time within 24 hours of the onset of thesymptoms of the Covid-19 disease.

In the following paragraphs, a description of symptoms and a timeline ofsymptoms are described from a disclosed patient that has suffered twooccurrences of the Covid-19 disease. The disclosed patient was treatedusing the disclosed herb thyme therapeutic treatment within twenty-fourhours after the symptoms started on each occurrences of the Covid-19disease. The disclosed patient recovered quickly from the symptoms ofthe disease at each occurrence and now appears to maintain immunity tothe disease after approximately fourteen months after the firstoccurrence of symptoms of the disease.

As described in the medical community, a second set of symptoms haveoccurred in some patients through the world after the patient hassuffered an initial set of symptoms of the disease, the second set ofsymptoms has been described as a re-infection. The term “re-infection”may be an inappropriate description since the virus may remain in thepatient's system for an extended period of time prolonging the infectionwithout symptoms of the infection, and the virus simply may re-activateits aggressive replication process. The second set of symptoms after aninitial recovery of the first set of symptoms resulting in an aggressivereplication process of the virus may be caused by a number of differentand unknown factors, although one factor to possibly cause the virus tore-activate its aggressive replication process may be the ingestion ofan substantial amount of sugar and fat such as cane sugar and milk creamin a food such as ice cream, this seemed to be the case as described bythe disclosed patient in the following paragraphs of this application.The disclosed patient believes the virus appears to feed off of thesugar and fat to gain strength from the availability of the sugar andfat in the patients system as this scenario seemed to be the scenariothat brought on the symptoms of Covid-19 in the disclosed patientsymptoms timeline of two occurrences of the Covid-19 disease thedisclosed patient suffered from. The first occurrence and first set ofsymptoms of the disease appeared in the disclosed patient approximatelyone hour after the ingestion of sugar and milk fat from ice cream andthe second occurrence and second set of symptoms of the disease appearedin the disclosed patient approximately one hour after the ingestion ofsugar and milk fat from a sweet milk tea drink containing sugar and fat.

The disclosed herb thyme treatment may or may not be effective inreducing the symptoms of an infected patient that has extensive ongoingand severe symptoms of the disease Covid-19 that requireshospitalization or other emergency care. In addition, the safety of thedisclosed treatment of Covid-19 using the herb thyme in a severely ormoderately infected person is unknown. The side effects of the disclosedtreatment seems to be few or none in a healthy patient when the patientis not currently or previous taken prescription drugs when the patientis treated within twenty four hours after the onset of symptoms andwherein the patient is still in basic good health and without breathingdifficulties, although this is not substantiated. There appears to beside effects related to orally ingesting of the herb thyme, one of theside effects being elevated blood pressure.

The administration of the disclosed herb thyme treatment in the abovementioned scenario and in the following description of occurrences thedisclosed patient has suffered has only been observed on one disclosedpatient and has not been observed on patients with severe symptoms thatwould require hospitalization or other emergency treatments for thedisease. Side effects and safety of the disclosed treatment is not knownwhen the disclosed treatment is administered to a patient with moderateor sever symptoms of the disease. In addition, the disclosed patientthat has received the disclosed herb thyme treatment in the disclosedlimited study was a healthy sixty one year old male with no underlyingconditions and has not been prescribed or taking any medications orother drugs. The effect of the disclosed treatment on a patient withunderlying conditions or a patient that is currently being treated withprescription or non-prescription drugs is not known. The disclosedpatient that was treated with the disclosed thyme herb treatment wassuffering from the symptoms of COVID-19, COVID-19 testing at thetimeline of March 2020 was not widely available, the disclosed patientwas not tested for COVID-19 at that time. The disclosed patient was verylikely infected and suffering from COVID-19 with many of the symptoms ofCovid-19, but testing verification was not attained. Future testing ofthe disclosed herbal thyme treatment of COVID-19 on additional patientswill verify the effectiveness of the disclosed herbal thyme treatment.

It is possible that a minimal maintenance dose of the disclosed thymetreatment given less often than the disclosed treatment of 0.2 ounces inthree oral administrations six to eight hours apart may result in apreventative therapy of the virus to re-activate its aggressivereplication process therefore preventing the patient from developingsymptoms of the disease. Long term side effects of a maintenance dose ofthe disclosed treatment of the disease is not known.

One active ingredient of the herb thyme is thymol. Treating a patientwith oil of thyme containing thymol may also be a beneficial treatmentalternative to using the entire herb in an unaltered but ground intopowder state. Additional extractions of the herb thyme may also be abeneficial alternative for oral ingestion for the treatment of Covid-19instead of oral administration of the entire herb leaf.

A presumed object of the disclosed invention and disclosed method of useseems to be to use the antiviral properties of the herb thyme to depressthe activity of the virus reducing the viruses ability to replicate andcause harm to the patient, thus allowing the patient to develop immunityto the virus while the virus is in a depressed state remaining in thepatient, although this is just a guess of the effect of the herb thymeon the Covid-19 disease and should not be a determination of fact.

The virus symptoms may resurface in the patient one or more times whilethe patient is developing immunity to the virus, requiring the patientto then again be treated with the disclosed invention method using theherb thyme utilizing the combination of anti-viral compounds in theherb. If for some reason the patient cannot or does not attain naturalimmunity to the virus with a reasonable timeframe such as thirty toninety days, the patient may opt to continue treatment with thedisclosed treatment each time the virus affects the patient in adebilitating or symptomatic manner while being diligent and aware of anypossible side affects from the ingestion of the herb thyme. One sideeffect of oral ingesting the herb thyme may be elevated blood pressure.Blood pressure monitoring during the disclosed thyme treatment may bebeneficial and a requirement during treatment for safety of the patient.Another side effect of the herb thyme may be that the oral ingestion ofthe herb may interact with drugs that slow blood clotting.

Using the herb thyme as an effective treatment to COVID-19 may have manyadvantages to the conventional treatment options described earlier inthis application. The herb thyme:

-   -   is a natural substance has been known to be possibly safe as        described when used as a medicine for short periods of time.    -   can be easily grown, is currently widely available to the        general public, and commonly sold in most grocery stores as a        food spice.    -   may be the most effect substance to use to assist the patient in        developing immunity to COVID-19 by simply inhibiting the        replication of the virus in the patient allowing the patient to        recover sufficiently to develop immunity.

Derivatives of the herb Thyme may also be an effective treatment optionfor the Covid-19 disease. One such derivative is the thymol. Thymol isfound in thyme oil or made synthetically. It may be noted, the disclosedpatient was treated with the entirety of the thyme leaf in a ground andpowdered state with all of the ingredients of the thyme leaf. Otherantiviral derivatives of thyme include, camphor, borneol, carvacrol,terpinenes, pinenes, cymene, terpinenols, citral and cineoles.

Below is a dated timeline of the disclosed patient scenario of symptomsand treatment of the symptoms of the coronavirus COVID-19 twooccurrences the patient suffered from.

Tuesday 2020-02-04: The disclosed patient having personal use experienceof ingesting thyme and its anti viral properties, ordered four six ouncepacks of thyme leaves from Amazon, brand name Yamees. The thyme orderwas received by the patient on 2020-02-06. The disclosed patient wasaware of the new coronavirus infection going around and made sure he hadan additional ample supplies of thyme to fight the infection if hecontracted the virus and of the possibility that the virus is deterredby the ingestion of the thyme powder. The disclosed patient promptlyground up one six ounce bag of thyme in the blender to make a roughpowder and placed the thyme powder is a sealed jar and placed the jar inthe refrigerator. On or near 2020-02-06 the disclosed patient alsopurchased a 1.38 ounce can of thyme powder from Fry's food store in theKroger brand.

Thursday 2020-02-06: The disclosed patient received his order of thymefrom Amazon.

Monday 2020-02-24: The disclosed patient purchased 2 lbs. of hulledsunflower seeds at Winco at 59^(th) Ave & Bell Rd. in Glendale Ariz. forabout $1.39 lb.

Monday 2020-02-24: The disclosed patient ate about 2 ounces of thesunflower seeds. The sunflower seeds tasted rancid with bad taste. Thedisclosed patient threw the portion of the sunflower seeds he did noteat in the trash. The disclosed patient is assuming that the sunflowerseeds were from China for the fact they only cost $1.39 per lb.

Monday 2020-02-24 through Sunday 2020-03-01 till 7 pm: The disclosedpatient felt fine without any noticeable health problems. The disclosedpatient worked in Camp Verde Ariz. on a small farm he owns on Saturdayand Sunday 02-29-20 and 03-01-20.

Sunday 2020-03-01 7:30 pm: The disclosed patient returned from thegrocery store (Bashes) in Camp Verde at about 7:30 pm and the disclosedpatient ate 1 pint of natural ice cream that had a high content of sugarand milk cream. The ice crème was Haagen Dazs pineapple coconut. Theingredients were Cream, skim milk, cane sugar, pineapple, egg yolks,natural flavor (contains coconut), rum.

Sunday 2020-03-01 8:00 pm: Soon after and with thirty to sixty minutesafter eating the ice cream the disclosed patient developed a slightfever and a slight headache with chills and aching in his bones. Thatnight the disclosed patient testing the soreness in his joints, tried todo a couple of pushups, the disclosed patient could not do any pushupsbecause of soreness in the shoulders, the shoulders are sore, thedisclosed patients shoulders are not normally sore when doing pushups.The disclosed patient's headache and fever persisted through out thenight.

Monday 2020-03-02 5:00 am: The disclosed patient is still felling sickbut not knowing what the problem is, the disclosed patient decided hecould not safely drive back to Phoenix in the morning darkness. Thedisclosed patient decided to go to the local restaurant in Camp VerdeAriz. called the Verde Café and eat breakfast before driving back toPhoenix during daylight hours.

Monday 2020-03-02 6:00 am to 7:00 am: The disclosed patient arrived atthe restaurant and sat down and ordered breakfast. The disclosed patientate the usual 2 eggs, hash browns, toast and coffee for the headache.The disclosed patient did not realize what his sickness could have been,nor did the patient communicate to any of the two or three other peoplesitting at the same table as the disclosed patient that the disclosedpatient was not feeling well. The disclosed patient did notice thatwhile sitting in the restaurant he was getting sharp pains in his lowerback in the kidney area, felt like being stabbed in the lower back and alittle to the side.

Monday 2020-03-02 9:30 am: The disclosed patient arrives in Phoenix andthe disclosed patient still not feeling well with a slight fever andheadache. The disclosed patient's single employee Brian says he isfinished with the current job schedule and ready to meet with thedisclosed patient at the next job at 51″ Ave & McDowell Rd where Brianand the disclosed patient need to complete some electrical circuittrouble shooting. Brian and the disclosed patient meet and finished thetrouble-shooting job by noon, the disclosed patient did not feel wellduring the work, but the job needed to be completed as it was behindschedule. The disclosed patient spent the rest of the day at homeresting.

Monday 2020-03-02 10:30 am: A former employee Jeff is in town fromWisconsin and sent the patient a text to see if the disclosed patient isin Phoenix. Jeff requested the disclosed patient help him grease thefront end of his truck as it is making noise. The disclosed patient toldhim sure, be glad to. The disclosed patient still was not feeling good,still did not know why or have any inclination he had contracted thecoronavirus Covid-19.

Monday 2020-03-02 2:10 pm: Although the disclosed patient is still notfeeling well and has no clue to what his sickness is

Monday 2020-03-02 3:00 pm: Still feeling bad with the persistent slightheadache and persistent slight fever, the disclosed patient is nowassuming he has Covid-19 disease and decided to start therapeutictreatment for himself with the herb thyme. For this first dose, thedisclosed patient used the bulk Thyme he purchased from Amazon that hehad previously ground up to a rough powder in his blender. The disclosedpatient added one heaping teaspoon (approximately 0.2 oz) into a fullglass of water and let the thyme sit in the water for about ½ hour untilthe thyme was soaked down with water. The disclosed patient thenproceeded to drink the entire glass of water containing the thyme. Thedisclosed patient had a small meal that day at El Pollo Loco at 51^(st)ave and McDowell Rd at about 11:00 am.

Monday 2020-03-02 8:00 pm: The disclosed patient is stilling fellingsick with the persistent slight headache, slight fever and body aches.The disclosed patient decided to ingest another heaping teaspoon dose ofthyme with water in the same manner as earlier except this time thepatient used the thyme powder in a small can he bought at the Fry'sgrocery store. The disclosed patient used one heaping teaspoon(approximately 0.2 oz) again and let the thyme powder sit in the waterbefore ingesting. The disclosed patient had mostly an empty stomach whenthe thyme was ingested. The disclosed patient is still feeling sick. Thedisclosed patient went to sleep. Prior to going to sleep, The disclosedpatient was thinking to himself that this sickness is nothing like Ihave ever felt before, the headache at the same time as the slight feverand tremendous joint pain was foreign to him even though the disclosedpatient has previously had the seasonal flu in years past, although thedisclosed patient has also treated the seasonal flu in the years pastwith the herb thyme and therefore he has not previously suffered to anylarge degree from the seasonal flu.

Tuesday 2020-03-03 4:30 am: The disclosed patient woke up after a nightof sleep where he did not sleep well. The headache had bothered thedisclosed patient all night and prevented him from sleeping well. Thefever was still with the disclosed patient, but the headache botheredhim more than the fever. The disclosed patient phone called the scheduleto his employee Brian to keep him busy most of the day.

Tuesday 2020-03-03 5:30 am: The disclosed patient is still feeling bad,the disclosed patient decided to ingest another heaping teaspoon dose ofthyme using the thyme powder in a small can he bought at the grocerystore. The disclosed patient ingested the thyme and water on an emptystomach.

Tuesday 2020-03-03 8:30 am: The disclosed patient started to feel muchbetter, the headache is reduced and the slight fever seems to be almostgone. The disclosed patient placed a automotive grease gun with greasein his truck expecting to meet with Jeff and grease his trucks frontend. The disclosed patient went out for a cup of coffee at 28^(th) Ave &Bell rd at The Gourmet Bagel coffee shop arriving at about 9:00 am. Thedisclosed patient sent a text to Jeff saying that he can grease histruck right now if he is available, but the disclosed patient told Jeffhe is feeling a little under the weather and probably should not meetwith his family incase he is contagious, Jeff responded Ok and met thepatient about 20 minutes later at the coffee shop. The disclosed patientgreased the zerk fittings on Jeff s truck and then the disclosed patientand Jeff talked old times for about 20 minutes in the parking lotlocated to the west side of the Fry's grocery store in the same vicinityof the coffee shop.

Tuesday 2020-03-03 11:00: The disclosed patient received a text from hisemployee, Brian saying he is finished with the job schedule and wouldlike to meet up at the storage at 43^(rd) & Peoria to install the newtruck door handle the patient bought for the bucket truck. The disclosedpatient and Brian met at about noon and installed the door handle, ittook about 2 hours complete and was a difficult job. The disclosedpatient was feeling better by now and working on the truck door handlewas not a great problem even though he was still a little weak. Thedisclosed patient gave Brian his schedule for Wednesday morning to firstthing go to the large centers in Surprise the company services.

Wednesday 2020-03-04 5:30 am: The disclosed patient is feeling prettygood, he texted Brian that he will meet him in Surprise. The disclosedpatient arrived in Surprise and worked a few hours with Brian on thecenters changing light bulbs and ballasts. The disclosed patient wasfeeling almost back to normal

Friday 2020-03-06 9:20 am: The disclosed patient is feeling fine againand pretty much back to normal except for a little weakness.

Friday 2020-03-06 through Wednesday 03-11-20: The patient is feelingpretty good and out in the field working with Brian, all seems normal.

Thursday 2020-03-12 6:00 am through 1:00 pm: The disclosed patientworked with Brian in the field most of the day and he worked fine. Thelast stop of the day was at Litchfield Rd and Van Buren street inAvondale. At about 1:00 pm the patient left to allow Brian to finish thejob while the disclosed patient went across the street for a cup ofcoffee to do some paperwork and to check the phone emails. The disclosedpatient ordered a coffee but the server said the coffee is real strongusing six shots of espresso, so the disclosed patient opted for a teainstead. The server said the tea is a milk tea and the disclosed patientsaid OK. The disclosed patient drank the tea and the tea was real sweet,too sweet for the disclosed patient's taste.

Thursday 2020-03-12 5:00 pm: A few hours after drinking the very sweetmilk tea, the disclosed patient started to get a headache and a slightfever with sore joints very similar to the same feeling he had on Sunday03-01-20 8:00 pm after eating the sweet ice cream. This time, thedisclosed patient says the sickness felt a little bit worse than the03-01-20 sickness. The disclosed patient gave himself a dose of thethyme at about 8:00 pm using the thyme he ground in his blender justlike previously and then went to sleep.

Friday 2020-03-13: The disclosed patient was pretty much sick all daywith a slight fever and a little more than a slight headache. Thedisclosed patient did not do too much all day, but he did give himselftwo more doses of the thyme from the can of thyme purchased from thegrocery store, each dose spaced out during the day about 8 hours apart.

Saturday 2020-03-14: The disclosed patient still felt a little sick onSaturday. The disclosed patient rested most of the day but was able toweed eat the grass at his house in Phoenix with a weed eater later inthe afternoon. The disclosed patient starting to feel better Saturdayevening, but not yet completely better.

Sunday 2020-03-15: The disclosed patient is feeling better today, heleft to travel up north to Camp Verde at about 11:00 am and arriving incamp Verde about 12:30 μm. The ground is too wet on the property fromrain to work on the property. The disclosed patient completed somepaperwork in his trailer for the rest of the day. The disclosed patientstayed the night in Camp Verde, the disclosed patient felt fine.

Monday 2020-03-16 4:30 am: The disclosed patient is feeling good today,he drove into Phoenix early in the morning and met Brian on the job at64^(th) street and Greenway road to help him work on a monument sign.

Monday 2020-03-23 4:00 pm: The disclosed patient ate 6 Valencia orangesthat are organic and picked from his backyard orange tree. The disclosedpatient experiences no ill effects from eating the high sugar orangesthe same day and in the days after eating the oranges.

Monday 2020-03-31 6:00 pm: The disclosed patient again ate 6 Valenciaoranges for a third time within four days. The disclosed patientexperiences no ill effects from eating the high sugar oranges the sameday and in the following days.

Thursday 2020-03-26 6:00 pm: The disclosed patient again ate 7 Valenciaoranges for a second time within nine days. The disclosed patientexperiences no ill effects from eating the high sugar oranges the sameday and in the following days. The disclosed patient experiences no illeffects from eating the high sugar oranges the same day and in thefollowing days.

Thursday 2020-04-02 7:00 am: The disclosed patient ate two high sugarand high fat donuts bought at Bosa Donuts at 75th ave and Cactus rd inGlendale Ariz. One donut was a strawberry and cheese croissant and theother donut was an apple-sugar filled donut. The disclosed patientexperienced no ill effects from eating the high sugar donuts the sameday. The disclosed patient performed labor the same day at the samelocation as the Bosa Donuts from 7:15 amp to 1:40 pm as he and hisemployee Brian provided electrical circuits to a monument sign on thesame property. The work consisted of medium to hard labor digging atrench and installing underground heavy metal conduit and then coveringthe conduit with excavated dirt, then proceeding to install theelectrical circuits.

Wednesday 2020-07-08 2:17 pm: The disclosed patient has not had arecurrence of Covid-19 symptoms since 03-03-2020 and 03-14-2020. Thedisclosed patient appears to have developed immunity to covid-19disease. The disclosed patient has eaten all types of food including fatand sugar. The disclosed patient has very rarely worn a facial maskexcept when in a large group of people like a grocery store whenrequired by the State of Arizona and the City of Phoenix. The disclosedpatient does not wear a mask while at work. The disclosed patient hasnot ingested any thyme powder or any type of thyme since 03-13-2020 andhas not experienced any Covid-19 symptoms up to the present of March 312021. The disclosed patient believes he has immunity and will notdevelop symptoms to the Covid-19 disease in the future for at least twoyears.

The sickness the disclosed patient had on 2020-03-01 and on 2020-03-12appeared to feel the same to the disclosed patient like it was the samesickness. The disclosed patient says it seems as though the virus stayedin his system after the first bout of symptoms on 2020-03-01, the thymetreatment seems to have weakened the virus. On 2020-03-01 the disclosedpatient was fine until he ate the very sweet ice cream that was loadedwith cane sugar. The disclosed patient's fever came on about twenty tosixty minutes after eating the ice cream.

Then again on 2020-03-12 after the patient ingested a large amount ofsugar from milk tea, he experienced very similar symptoms he had on2020-03-01. The disclosed patient says it appears the virus was stillalive in his system just waiting to be fed a good amount of sugar tostart aggressive replication and affecting his body again.

The disclosed patient feels that the thyme does not kill the virus, butthat the thyme inhibits the virus enough to allow the body to attack thevirus with the body's immune system. The disclosed patient says itappears three heaping teaspoon doses of the thyme mixed with water andeach dose of one heaping teaspoon of thyme powder taken about 8 hoursapart is enough to inhibit the virus to get the desired result ofrecovery started. The disclosed patient also feels it also appears thatsugar and fat feeds the virus and increases its replication intervalsand severity of the symptoms.

The disclosed patient feels that a minimal single dose of approximately⅛ of a heaping teaspoon of thyme powder everyday ingested in theprevious stated method will act as a deterrent to symptoms flaring upafter a patient has been infected and recovered from Covid-19. Thedisclosed patient feels that ingesting thyme leaves soaked in water thatare not ground up into powder may not duplicate the favorable effects ofthe treatment the disclosed patient experienced when he treated thecoronavirus infection with thyme powder soaked in water. The disclosedtreatment for COVID-19 is the oral ingestion of the herb thyme in aground, powdered form and soaked in a liquid such as water for aboutthirty minutes and then ingested with the liquid. Six to ten ounces ofwater may be used to soak the thyme in and the water is to be drank withthe ingestion of the thyme. The treatment is meant for a patient thathas an onset of symptoms such as symptoms comprising but not limited toindividually or in combination thereof fever, headache, sore joints,cough, fatigue, chills usually with the last one to three days. Thedisclosed patient initial infection of the virus seems to be betweenfive to ten days prior to the onset of symptoms if the disclosed patientis right about being infected with the coronavirus form the sunflowerseeds he ingested.

The method for treatment for a dose is to add approximately one heapingteaspoon (approximately 0.2 ounces) of ground, powdered Thyme to a sixto ten ounces of water in a glass residing in a room temperature(approximately 70 degrees F.) environment. Before drinking the water andthe Thyme mixture, the water and thyme powder should sit idly for aboutthirty minutes to allow the water to soak fully into the Thyme powder,hydrating the Thyme powder fully and allowing the mixture to be stirredwith the Thyme powder dispersing the Thyme powder into the water withoutany dry Thyme powder residing on top of the water surface.

The patient should then drink the first dose of water and Thyme powderwithin a one half hour timeframe. A second dose of Thyme powder andwater should be orally ingested about six to eight hours after the firstdose. A third dose of thyme and water should be orally ingested aboutsix to eight hours after the second dose. The patient should rest orsleep if possible through out the dosing process. The patient may notfeel any relief from the COVID-19 symptoms until after the third dose ofthe thyme powder and water, and any relief may take three to six hoursafter the third dose depending on the severity of the infection. In thetime between the first dose and the third dose oft the thyme powder, itmay be beneficial for the patient to refrain from eating food or justeat very light food during this time.

The single disclosed patient in the study felt relief approximatelythree hours after the third dose of the thyme powder and water. If apatient does not feel relief from the symptoms within eight hours afterthe third dose of thyme powder and water, a fourth dose may beconsidered depending on the patients condition or possible side effectsof the thyme powder and water mixture. The patient should also keep inmind any possible side effects that may occur with the thyme powder andwater interacting with prescription or non-prescription drugs,especially blood thinners.

One object of this disclosed invention is for the patient to develop andgain immunity to allow his or her immune system to fight and contain thereplication of the virus, therefore preventing symptoms to appear in thepatient when the patient harbors the virus. The preferred method in thedisclosed invention of gaining immunity to the virus is for the patientto participate in a regime of oral ingestion of thyme and water in threeor more doses. The patient may require one or more regimes or oralingestion of the thyme and water if the symptoms of the disease reappearafter the first regime. Each regime will be ingested intermittently witha period of time between each regime to allow the patients immune systemto perform the work of fighting the virus when the virus is in aweakened state. The period of time between each regime is usually in therange of one week to four weeks depending on the patient and thepatients health and diet and when or if the symptoms reappear, theintake of sugar should be restricted during the immunity building timeperiod so as to not feed the virus a preferred nutrient of the virus.The number of regimes needed for the patient to build immunity againstthe virus will also depend on the patents health, age and diet. Thepossibility exists that some patients will not be able to developsufficient immunity to fight off symptoms of the viral infection and mayneed to ingest the thyme and water on a regular basis or seek additionalmedical treatment of a different type. The single patient in thedisclosed study required a second regime of thyme and waterapproximately two weeks after the first regime. The second set ofsymptoms appearing soon after the patient ingested a large amount ofsugar and fat in a milk tea drink. The second set of symptoms reappearedwithin two hours after the sugar infused tea drink was ingested. As ofthe date of this writing (2021-03-31), it has been one year since theonset of the second set of symptoms with no re-occurrence of symptoms athird time even though the patient has ingested a moderate amount ofsugar and fat by eating donuts, ice cream and oranges, the oranges beingof the Valencia variety known for a high sugar content. It appears thepatient has developed immunity or at least partial immunity to thevirus, additional time will tell in the months ahead.

The testing of a single patient is preliminary and further testing needsto be accomplished to verify the effectiveness and safety of thedisclosed treatment for all different types of patients with differentmedical conditions or deficiencies. This treatment method using thymeand water was successful on only one patient and is not medical advicefor any individual.

Extracted components of the herb thyme either singularly, mixed withother extracted components of the herb or mixed with the entire leaf ofthe herb may be very effective in the treatment of Covid-19 disease. Acomposition comprising of i) the whole leaf of the herb thyme, or ii)one or more extracted components of the whole leaf of the herb thyme, oriii) a mixture of the whole leaf of the herb thyme combined with one ormore extracted components of the whole leaf of the herb thyme for oralingestion should be the basis for the treatment or the prevention of thedisease Covid-19. The herb thyme may be more effective in a ground stateinstead of a whole state in the treatment of Covid-19. The herb in theground state may allow the herb to digest more effectively in thedigestive system of the patient. In addition, the method of combiningthe ground state of the herb or the whole thyme leaf with a liquid suchas water may also improve the effectiveness of the digestion system indigesting the herb. Another alternative may be for the herb thyme to becombined with food for the prevention or treatment of the diseaseCovid-19. Synthetic thymol may also be an alternative to the naturalform of thymol form the herb thyme when used as an active ingredient forthe treatment or prevention of Covid-19 disease.

A broad method for using the composition of claim 1 for use in thetreatment of the disease Covid-19 disease in a patient experiencing thebeginning stages of the symptoms of the disease, the treatment beginningwithin approximately twenty-four hours after the onset of COVID-19symptoms that may comprise of but are not limited to individually orlimited to in combination thereof; fever, headache, sore joints, cough,fatigue, and chills, the method of use comprising the steps of:

-   -   a) orally ingesting a first dose of the herb thyme,    -   b) orally ingesting a second dose of the herb thyme within        approximately six to eight hours after the first dose of the        herb thyme, and    -   c) orally ingesting a third dose of the herb thyme within        approximately six to eight hours after the second dose of the        herb thyme.

A detailed method for using the herb thyme for use in the treatment ofCOVID-19 disease in a patient experiencing the beginning stages of thesymptoms of the disease, the treatment beginning within approximatelytwenty-four hours after the onset of COVID-19 symptoms that may compriseof but are not limited to individually or limited to in combinationthereof; fever, headache, sore joints, cough, fatigue, and chills, themethod of use comprising the steps of:

-   -   a) the patient staying hydrated with water throughout the entire        treatment duration,    -   b) creating a test dose of the herb thyme in a ground state of        thyme and water to prepare for oral ingestion of the test dose        of the thyme powder and the water, the test dose is to determine        if the patient has an abnormal or dangerous reaction to the        ingestion of a larger dose of the thyme powder and the water,        the abnormal or dangerous reaction may consist of a blood        pressure or pulse increase in the patient that might be        considered to be dangerous to the patients health, creating the        test dose of the thyme powder and water comprising the steps of:        -   i) placing a quarter teaspoon of approximately 0.05 ounces            of powdered thyme in six to twelve ounces of water in an            environment of air temperature at about seventy degrees            Fahrenheit, the water temperature also being about seventy            degrees Fahrenheit in temperature,        -   ii) the thyme powder will generally initially float on the            surface of the water, and        -   iii) allowing the thyme to set in the water for thirty            minutes or until the water has fully saturated the thyme            powder allowing the thyme powder to be stirred and mixed            into the water without any dry thyme powder remaining            floating on the surface of the water,    -   c) prior to orally ingesting the test dose of the thyme powder        and water, the patient is monitored by taking and recording the        vital signs of the patient including but not limited to: the        pulse rate, the body temperature, and the blood pressure, all        vital signs taken and recorded while the patient is resting,    -   d) the patient orally ingests the test dose of the thyme powder        and water, the entirety of the thyme powder and water being        orally ingested within a thirty minute timeframe,    -   e) the patient being monitored for at least one hour after        orally ingesting the test dose, the monitoring of the patient        includes recording the vital signs of the patient including but        not limited to; the pulse rate, the body temperature, and the        blood pressure while resting,    -   f) if the patient does not have an abnormal or dangerous        reaction to the test dose such as a blood pressure or a pulse        rate increase in the patient that might be considered to be        dangerous to the patients health, the patient will immediately        orally ingest a first dose of the thyme power and water after        creating the first dose of the thyme powder and water,    -   g) the patient or patients assistant creates a first dose of        powdered thyme and water to prepare for oral ingestion of the        thyme powder and the water, creating the first dose of the thyme        powder and water comprising the steps of:        -   i) placing a heaping teaspoon of approximately 0.2 ounces of            ground powdered thyme in six to twelve ounces of water in an            environment of air temperature at about seventy degrees            Fahrenheit, the water temperature also being about seventy            degrees Fahrenheit in temperature,        -   ii) the thyme powder will generally float on the surface of            the water, and        -   iii) allowing the thyme to set in the water for thirty            minutes or until the water has fully saturated the thyme            powder allowing the thyme powder to be stirred and mixed            into the water without any dry thyme powder remaining on the            surface of the water,    -   h) the patient ingests the first dose of the thyme powder and        water,    -   i) the patient is monitored for at least one hour after orally        ingesting the first dose of thyme powder and water, the        monitoring of the patient includes periodically recording the        vital signs of the patient including but not limited to; the        pulse rate, the body temperature, and the blood pressure while        resting,    -   j) if the patient does not have an abnormal or dangerous        reaction to the first dose such as a blood pressure or pulse        increase in the patient that might be considered to be dangerous        to the patients health, the patient will rest for six to eight        hours until taking a second dose of the thyme powder and water.        If the patient has an abnormal or dangerous reaction to the        first dose, the patient seeks medical attention,    -   k) six to eight hours after the first dose of thyme powder and        water was orally ingested by the patient, the patient or the        patient's assistant creates a second dose of the powdered thyme        and water in the same manner the first dose was created, and the        patent orally ingests the second dose of the thyme powder and        water in the same manner as the first dose, preferably        refraining from food and sugars between the first dose and        second dose of the thyme powder and water,    -   l) the patient is monitored for at least one hour after orally        ingesting the second dose of thyme powder and water, the        monitoring of the patient includes periodically recording the        vital signs of the patient including but not limited to; the        pulse rate, the body temperature, and the blood pressure while        resting,    -   m) if the patient does not have an abnormal or dangerous        reaction to the second dose such as a blood pressure or pulse        increase in the patient that might be considered to be dangerous        to the patients health, the patient will rest for six to eight        hours until taking a third dose of the thyme powder and water.        If the patient has an abnormal or dangerous reaction to the        second dose, the patient seeks medical attention,    -   n) six to eight hours after the second dose of thyme powder and        water was ingested by the patient, the patient or the patient's        assistant creates a third dose of the powdered thyme and water        in the same manner the first and the second dose was created,        and the patient orally ingests the third dose of the thyme        powder and water in the same manner as the first dose and the        second dose was orally ingested, preferably refraining from food        and sugars between the second dose and third dose of the thyme        powder and water,    -   o) the patient preferably refrains from food and sugars for four        to six hours after the third dose of the powdered thyme and        water,    -   p) the patient is monitored for at least one hour after orally        ingesting the second dose of thyme powder and water, the        monitoring of the patient includes periodically recording the        vital signs of the patient including but not limited to; the        pulse rate, the body temperature, and the blood pressure while        resting. If the patient has an abnormal or dangerous reaction to        the third dose, the patient seeks medical attention,    -   q) the patient stays hydrated prior to the first dose of thyme        powder and after the third dose of thyme powder and water,    -   r) eight hours after the third dose of the thyme powder and        water, the patient is again monitored for improvement of        symptoms of the disease, if the symptoms of the disease do not        improve, the patient should seek additional medical care from a        health care provider, and        -   the dosage quantities are formulated for a healthy one            hundred and seventy pound male 62 years of age with no            pre-existing medical conditions such and high blood pressure            or diabetes, the dosage formulations may need to be adjusted            for a younger or older person that is either lighter in            weight or heavier in weight, monitoring of the patient by a            health care professional is strongly recommended and may be            necessary for the safety of the patient.

Alternative methods of orally ingesting the herb thyme or its activeingredients may be in other forms such as a pill or a capsule. A pill orcapsule form may be a much more pleasant way of ingesting the herb thymesince the herb in a powder state and mixed with a liquid such as watercan be a very bitter solution to ingest and may be repugnant to somepeople. The effectiveness of a pill or a capsule form in treating thedisease Covid-19 may be diminished if complete digestion is notattained. In addition stomach or intestinal irritation may develop insome forms of ingestion of the herb.

I claim:
 1. A composition for oral ingestion for use in the treatment ofthe disease Covid-19, the composition comprising one or more extractedcomponents of the whole leaf of the herb thyme.
 2. The composition ofclaim 1 in a ground state.
 3. The composition of claim 2 combined with aliquid.
 4. The composition of claim 3 wherein the liquid compriseswater.
 5. The composition of claim 2 combined with food.
 6. Thecomposition of claim 2 encapsulated or formed into a pill.
 7. Thecomposition of claim 1 for use in the prevention of the diseaseCovid-19.
 8. The composition of claim 7 in a ground state.
 9. Thecomposition of claim 8 combined with a liquid.
 10. The composition ofclaim 9 wherein the liquid comprises water.
 11. The composition of claim8 combined with food.
 12. The composition of claim 8 encapsulated orformed into a pill.
 13. The substance thymol in a synthetic form for usein the treatment of the disease Covid-19.
 14. The substance thymolderived from the herb thyme, for use in the treatment of the diseaseCovid-19.
 15. The composition of claim 1 comprising any one ofindividually the constituents or in combination thereof theconstituents, the constituents being, thymol, camphor, borneol,carvacrol, terpinenes, pinenes, cymene, terpinenols, citral andcineoles, for use in the treatment or prevention of the diseaseCovid-19.
 16. A method for using the composition of claim 1 for use inthe treatment of the disease Covid-19 disease in a patient experiencingthe beginning stages of the symptoms of the disease, the treatmentbeginning within approximately twenty-four hours after the onset ofCOVID-19 symptoms that may comprise of but are not limited toindividually or limited to in combination thereof; fever, headache, sorejoints, cough, fatigue, and chills, the method of use comprising thesteps of: i) orally ingesting a first dose of the one or more extractedcomponents of the whole leaf of the herb thyme. ii) orally ingesting asecond dose of the one or more extracted components of the whole leaf ofthe herb thyme within approximately six to eight hours after the firstdose of the herb thyme, and iii) orally ingesting a third dose of theone or more extracted components of the whole leaf of the herb thymewithin approximately six to eight hours after the second dose of theherb thyme.
 17. The method of claim 16 wherein the one or more extractedcomponents of the whole leaf of the herb thyme is orally ingested with aliquid.
 18. The method of claim 17 wherein the liquid comprises water.19. The method of claim 16 wherein the one or more extracted componentsof the whole leaf of the herb thyme is orally ingested with food. 20.(canceled)